EA201991304A1 - 5-[[4-[2-[5-(1-гидроксиэтил)пиридин-2-ил]этокси]фенил]метил]-1,3-тиазолидин-2,4-дион для лечения неалкогольной жировой болезни печени - Google Patents

5-[[4-[2-[5-(1-гидроксиэтил)пиридин-2-ил]этокси]фенил]метил]-1,3-тиазолидин-2,4-дион для лечения неалкогольной жировой болезни печени

Info

Publication number
EA201991304A1
EA201991304A1 EA201991304A EA201991304A EA201991304A1 EA 201991304 A1 EA201991304 A1 EA 201991304A1 EA 201991304 A EA201991304 A EA 201991304A EA 201991304 A EA201991304 A EA 201991304A EA 201991304 A1 EA201991304 A1 EA 201991304A1
Authority
EA
Eurasian Patent Office
Prior art keywords
disease
thiazolidine
pyridin
ethoxy
hydroxyethyl
Prior art date
Application number
EA201991304A
Other languages
English (en)
Inventor
Мария Пилар Пискуэта Лаланса
Марк Мартинель Педемонте
Original Assignee
Минорикс Терапьютикс С.Л.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Минорикс Терапьютикс С.Л. filed Critical Минорикс Терапьютикс С.Л.
Publication of EA201991304A1 publication Critical patent/EA201991304A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Настоящее изобретение относится к способу лечения или профилактики неалкогольной жировой болезни печени, неалкогольного стеатогепатита, хронического гранулематозного заболевания, синдрома поликистозных яичников, рака щитовидной железы, аутоиммунного заболевания щитовидной железы, аденомы гипофиза, атеросклероза, гипертензии, кожного заболевания, воспалительного и аутоиммунного заболевания и воспалительного заболевания органов дыхания путем введения 5-[[4-[2-[5-(1-гидроксиэтил)пиридин-2-ил]этокси]фенил]метил]-1,3-тиазолидин-2,4-диона нуждающемуся в этом субъекту. Изобретение также относится к 5-[[4-[2-[5-(1-гидроксиэтил)пиридин-2-ил]этокси]фенил]метил]-1,3-тиазолидин-2,4-диону для применения в фармацевтической композиции или в производстве лекарственного средства для лечения или профилактики неалкогольной жировой болезни печени или неалкогольного стеатогепатита.
EA201991304A 2016-12-01 2017-12-01 5-[[4-[2-[5-(1-гидроксиэтил)пиридин-2-ил]этокси]фенил]метил]-1,3-тиазолидин-2,4-дион для лечения неалкогольной жировой болезни печени EA201991304A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16382584 2016-12-01
PCT/IB2017/057587 WO2018100557A1 (en) 2016-12-01 2017-12-01 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine- 2,4-dione for treating nonalcoholic fatty liver disease

Publications (1)

Publication Number Publication Date
EA201991304A1 true EA201991304A1 (ru) 2019-12-30

Family

ID=57517838

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201991304A EA201991304A1 (ru) 2016-12-01 2017-12-01 5-[[4-[2-[5-(1-гидроксиэтил)пиридин-2-ил]этокси]фенил]метил]-1,3-тиазолидин-2,4-дион для лечения неалкогольной жировой болезни печени

Country Status (20)

Country Link
US (1) US11938122B2 (ru)
EP (1) EP3548026B1 (ru)
JP (1) JP7040798B2 (ru)
KR (1) KR102595034B1 (ru)
CN (1) CN110022877B (ru)
AU (1) AU2017370003B2 (ru)
BR (1) BR112019011334A2 (ru)
CA (1) CA3044364A1 (ru)
CY (1) CY1124116T1 (ru)
DK (1) DK3548026T3 (ru)
EA (1) EA201991304A1 (ru)
ES (1) ES2867300T3 (ru)
HR (1) HRP20210576T1 (ru)
HU (1) HUE054346T2 (ru)
LT (1) LT3548026T (ru)
MX (1) MX2019006066A (ru)
PL (1) PL3548026T3 (ru)
PT (1) PT3548026T (ru)
SI (1) SI3548026T1 (ru)
WO (1) WO2018100557A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3548026T3 (pl) 2016-12-01 2021-08-23 Minoryx Therapeutics S.L. 5-[[4-[2-[5-(1-hydroksyetylo)pirydyn-2-ylo]etoksy]fenylo]metylo]-1,3-tiazolidyno-2,4-dion do leczenia niealkoholowej stłuszczeniowej choroby wątroby
JP7376934B2 (ja) 2018-06-06 2023-11-09 ミノリックス セラピューティクス エセ．エレ． ミトコンドリア性疾患の処置における使用のための５－［［４－［２－［５－（１－ヒドロキシエチル）ピリジン－２－イル］エトキシ］フェニル］メチル］－１，３－チアゾリジン－２，４－ジオンおよびその塩
EP4142720A1 (en) * 2020-04-30 2023-03-08 Minoryx Therapeutics S.L. Leriglitazone for treating lung inflammation and interstitial lung disease
WO2024141951A1 (en) 2022-12-28 2024-07-04 Minoryx Therapeutics S.L. Optimized dosing of leriglitazone

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE202352T1 (de) * 1991-04-11 2001-07-15 Upjohn Co Thiazolidindionderivate, herstellung und anwendung
US5441971A (en) 1991-04-11 1995-08-15 The Upjohn Company Thiazolidinedione derivatives, production and use thereof
AU4104593A (en) 1992-05-05 1993-11-29 Upjohn Company, The A process for producing pioglitazone metabolite
US5952509A (en) 1996-06-27 1999-09-14 Takeda Chemical Industries, Ltd. Production of benzaldehyde compounds
US6191154B1 (en) 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
EP1465627B1 (en) 2001-12-21 2006-03-08 SmithKline Beecham Corporation DOSING REGIMEN FOR PPAR−GAMMA ACTIVATORS
US8993773B2 (en) 2002-07-16 2015-03-31 Cadila Healthcare Limited Process to prepare pioglitazone via several novel intermediates
GB0510469D0 (en) * 2005-05-23 2005-06-29 Leuven K U Res & Dev Insulin sensitization to slow down pubertal tempo and to augment pubertal growth
MX2008011871A (es) 2006-03-16 2009-02-10 Metabolic Solutions Dev Compan Analogos de tiazolidindiona para el tratamiento de enfermedad mediada por inflamacion metabolica.
US8722710B2 (en) 2007-09-26 2014-05-13 Deuterx, Llc Deuterium-enriched pioglitazone
US8895537B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating cardiovascular diseases
US20150224120A1 (en) 2011-09-14 2015-08-13 Catherine Clelland Compositions and methods for treating hyperprolinemia-associated mental disorders
US8865747B2 (en) 2012-03-23 2014-10-21 Fundació Institute D'Investigació Biomėdica de Bellvitge (IDIBELL) Pioglitazone for use in the treatment of adrenoleukodystrophy
US20140178456A1 (en) 2012-08-30 2014-06-26 Udaya Sankar Devanaboyina Methods and compositions for treating type 2 diabetes and related conditions
WO2014152843A1 (en) 2013-03-14 2014-09-25 Deuterx, Llc Deuterium-enriched 2,4-thiazolidinediones and methods of treatment
ES2831326T3 (es) 2014-01-15 2021-06-08 Poxel Sa Métodos para tratar trastornos neurológicos, metabólicos y otros mediante el uso de pioglitazona enantiopura enriquecida con deuterio
EA035866B1 (ru) * 2014-04-02 2020-08-21 Минорикс Терапьютикс С.Л. Применение производных 2,4-тиазолидиндиона для лечения расстройств центральной нервной системы и способ лечения с использованием таких производных
PL3548026T3 (pl) 2016-12-01 2021-08-23 Minoryx Therapeutics S.L. 5-[[4-[2-[5-(1-hydroksyetylo)pirydyn-2-ylo]etoksy]fenylo]metylo]-1,3-tiazolidyno-2,4-dion do leczenia niealkoholowej stłuszczeniowej choroby wątroby

Also Published As

Publication number Publication date
JP7040798B2 (ja) 2022-03-23
PL3548026T3 (pl) 2021-08-23
DK3548026T3 (da) 2021-04-19
HUE054346T2 (hu) 2021-08-30
BR112019011334A2 (pt) 2019-10-15
MX2019006066A (es) 2019-09-10
PT3548026T (pt) 2021-04-22
AU2017370003A1 (en) 2019-06-06
AU2017370003B2 (en) 2023-04-13
EP3548026A1 (en) 2019-10-09
LT3548026T (lt) 2021-05-25
CA3044364A1 (en) 2018-06-07
WO2018100557A1 (en) 2018-06-07
CN110022877B (zh) 2023-06-23
US20200093812A1 (en) 2020-03-26
JP2020500868A (ja) 2020-01-16
EP3548026B1 (en) 2021-01-20
KR102595034B1 (ko) 2023-10-26
KR20190086766A (ko) 2019-07-23
HRP20210576T1 (hr) 2021-05-28
SI3548026T1 (sl) 2021-07-30
US11938122B2 (en) 2024-03-26
ES2867300T3 (es) 2021-10-20
CY1124116T1 (el) 2022-05-27
CN110022877A (zh) 2019-07-16

Similar Documents

Publication Publication Date Title
EA201991304A1 (ru) 5-[[4-[2-[5-(1-гидроксиэтил)пиридин-2-ил]этокси]фенил]метил]-1,3-тиазолидин-2,4-дион для лечения неалкогольной жировой болезни печени
MX2022007607A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostericos de shp2.
JP2018523676A5 (ru)
PE20142292A1 (es) Composiciones parasiticidas que comprenden un agente activo de isoxazolina, sus metodos y usos
AR116394A2 (es) Mesilato de n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)fenil]acetamida monohidrato
EA202091120A3 (ru) Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы
CR20130649A (es) Liberación modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida solubilizada utilizando ácidos orgánicos
PH12015501795A1 (en) A novel composition for nonalcoholic fatty liver disease (nafld)
RU2018140960A (ru) Композиции, содержащие комбинированный состав на основе антител к pd-l1 и ctla-4
MX2019001814A (es) Tratamiento y remision virologica sostenida de infeccion de vih mediante anticuerpos a cd4 en pacientes estabilizados con haart.
MX2018005715A (es) Uso de antagonistas del receptor ep4 para el tratamiento de cancer de higado asociado con nash.
EA201491007A1 (ru) Лекарственные составы
RU2018114077A (ru) Биарильное производное и содержащее его лекарственное средство
MX2019007327A (es) Proceso para preparar 5-[[4-[2-[5-(1-hidroxietil)-2-piridinil] etoxi]fenil]metil]-2,4-tiazolidindiona y sus sales.
IL279183A (en) Method for administering a therapeutically effective amount of 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1, 3-thiazolidine-2, 4-dione
EA025948B1 (ru) КОМБИНАЦИЯ ИНГИБИТОРА ФОСФАТИДИЛИНОЗИТ-3-КИНАЗЫ (PI3K) И ИНГИБИТОРА mTOR
EA202092954A1 (ru) Применение 5-[4-[2-[5-ацетилпиридин-2-ил]этокси]бензил]-1,3-тиазолидин-2,4-диона и его солей
MX2017013788A (es) Composicion farmaceutica estabilizada.
EA201692514A1 (ru) Фармацевтические композиции на основе софосбувира и рибавирина с модифицированным высвобождением
PE20141353A1 (es) Derivado de acido pirrolidin-3-ilacetico
EA201692515A1 (ru) Новая фармацевтическая композиция на основе софосбувира и рибавирина
EA201690762A1 (ru) {4-[5-(3-хлорфенокси)оксазоло[5,4-d]пиримидин-2-ил]-2,6-диметилфенокси}уксусная кислота для применения при предупреждении или лечении острого повреждения почек
AR098003A1 (es) Inhibidores de kras g12c
EA202091821A1 (ru) Ингибиторы cd73
NZ618904A (en) Pyridin-2(1h)-one derivatives as jak inhibitors